US10568855 — Compositions and methods for enhancing the efficacy of contraceptive microbicides
Method of Use · Assigned to Evofem Inc · Expires 2033-03-15 · 7y remaining
What this patent protects
This patent protects compositions and methods that combine a contraceptive microbicide with an antiviral agent to prevent pregnancy and reduce the risk of spreading sexually transmitted diseases.
USPTO Abstract
The present disclosure relates to compositions and methods for contraception that also enhance the efficacy of microbicides. Such compositions serve the dual purpose of preventing pregnancy and lessening the risk of spreading sexually transmitted diseases. More specifically, the compositions and methods relate to syngergistic contraceptive microbicide and antiviral compositions comprising a combination of a contraceptive microbicide and an antiviral agent in an acidic carrier that enhances the efficacy of both the contraceptive microbicide and antiviral agent.
Drugs covered by this patent
- Renacidin (CITRIC ACID) · Baxter
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1 |
Treatment of a specific disease/condition (broad) | Renacidin |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.